Astrana Health price target raised to $48 from $45 at Stifel

Stifel raised the firm’s price target on Astrana Health to $48 from $45 and keeps a Buy rating on the shares. The firm came away from meetings with management incrementally more positive about the company’s near- and medium-term prospects as well as its ability to continue to expand its business outside of California, the analyst tells investors in a research note.